News from soligenix, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 24, 2014, 09:23 ET

Soligenix Announces Closing of Public Offering of Units

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Dec 19, 2014, 08:24 ET

Soligenix Announces Pricing of Public Offering of Units

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Dec 11, 2014, 07:00 ET

Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Dec 10, 2014, 07:00 ET

Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Nov 17, 2014, 07:15 ET

Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Nov 10, 2014, 07:00 ET

Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 23, 2014, 07:00 ET

Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 19, 2014, 07:00 ET

Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Sep 17, 2014, 07:00 ET

Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 09, 2014, 07:00 ET

Soligenix Announces Issuance of US Patent for ThermoVax™ Technology

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 08, 2014, 07:00 ET

Soligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 05, 2014, 07:00 ET

Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Sep 02, 2014, 07:00 ET

Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat...

Aug 11, 2014, 07:30 ET

Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat...

Aug 07, 2014, 07:00 ET

Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on...

Aug 01, 2014, 07:30 ET

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat...

Jul 09, 2014, 07:00 ET

Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat...

May 12, 2014, 07:15 ET

Soligenix Reports First Quarter 2014 Financial Results, and Highlights Recent Accomplishments

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat...

Apr 07, 2014, 07:15 ET

Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat...

Mar 26, 2014, 07:15 ET

Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat...